The Committee for Medicinal Products for Human Use have approved Novartis drug in those women who are postmenopausal and have cancer that has recurred or progressed further after treatment. If the European Medicines Agency follows the recommendation, Afinitor will be approved in 27 European Union countries as well as Iceland and Norway.
The treatment is already approved as a treatment for kidney and pancreas cancer, as well as tuberous sclerosis. It is taken as a pill, once per day and could help the 20,000 women globally that are diagnosed with this advanced form of breast cancer. After their diagnosis, these patients typically have a life expectancy of 18-36 months.